Jane Huang - 02 May 2022 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Role
President, CMO
Signature
/s/ Laurent Chardonnet, Attorney-in-Fact
Issuer symbol
PRLD
Transactions as of
02 May 2022
Net transactions value
$0
Form type
4
Filing time
04 May 2022, 17:46:02 UTC
Previous filing
06 Apr 2022
Next filing
09 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRLD Employee Stock Option (Right to Buy) Award $0 +460,000 $0.000000 460,000 02 May 2022 Common Stock 460,000 $4.86 Direct F1
transaction PRLD Restricted Stock Unit Award $0 +150,000 $0.000000 150,000 02 May 2022 Common Stock 150,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 25% of the total shares on April 4, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F3 The RSUs shall vest as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date.